Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables (2016 - 2025)

Historic Receivables for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $73.5 million.

  • Corcept Therapeutics' Receivables rose 1742.66% to $73.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.5 million, marking a year-over-year increase of 1742.66%. This contributed to the annual value of $54.0 million for FY2024, which is 2604.44% up from last year.
  • Per Corcept Therapeutics' latest filing, its Receivables stood at $73.5 million for Q3 2025, which was up 1742.66% from $68.7 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Receivables registered a high of $80.0 million during Q1 2025, and its lowest value of $23.9 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables was $46.6 million (2023), whereas its average is $46.7 million.
  • Per our database at Business Quant, Corcept Therapeutics' Receivables plummeted by 1489.82% in 2021 and then skyrocketed by 6522.46% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Receivables stood at $29.0 million in 2021, then soared by 55.24% to $45.1 million in 2022, then dropped by 4.96% to $42.8 million in 2023, then surged by 35.62% to $58.1 million in 2024, then rose by 26.61% to $73.5 million in 2025.
  • Its Receivables stands at $73.5 million for Q3 2025, versus $68.7 million for Q2 2025 and $80.0 million for Q1 2025.